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Introduction: Activation of the sympathetic nervous system has beneficial cardiovascular effects in sepsis, but there is
also evidence that sympatholytics have beneficial actions in sepsis. We therefore determined the effect of selective
β1-adrenoceptor blockade on cardiac and renal function and cytokine release in ovine hyperdynamic sepsis.
Methods: Hyperdynamic sepsis was induced by infusion of live E. coli for 24 hours in nine conscious sheep
instrumented with flow probes on the pulmonary and left renal artery. Cardiovascular and renal function and levels of
plasma cytokines were determined in a control group and during selective β1-adrenoceptor blockade with atenolol
(10 mg intravenous bolus then 0.125 mg/kg/h) from 8 to 24 hours of sepsis.
Results: Hyperdynamic sepsis was characterized by hypotension with increases in cardiac output (CO), heart rate (HR)
and renal blood flow (RBF), and acute kidney injury. Atenolol caused sustained reductions in HR (P <0.001) and CO
(P <0.001). Despite the lower CO the sepsis-induced fall in mean arterial pressure (MAP) was similar in both groups. The
sepsis-induced increase in RBF, decrease in renal function and increase in arterial lactate were unaffected by atenolol.
Sepsis increased plasma levels of tumour necrosis factor alpha (TNF-α), interleukin 6 (IL-6) and IL-10. Atenolol caused a
further increase in IL-10, but did not affect levels of TNF-α or IL-6.
Conclusions: In sepsis, selective β1-adrenoceptor blockade reduced CO, but not MAP. During sepsis, atenolol
did not alter the development of acute kidney injury or the levels of pro-inflammatory cytokines, but enhanced
the release of IL-10. Atenolol appears safe in sepsis, has no deleterious cardiovascular or renal effects, and has
an anti-inflammatory effect.Introduction
Widespread activation of the sympathetic nervous sys-
tem is a well-known phenomenon in sepsis and septic
shock [1-3]. An increase in sympathetic nerve activity
would be expected to be beneficial in sepsis to maintain
arterial pressure and organ perfusion, and indeed treat-
ment with noradrenaline is the first-choice vasopressor
to maintain arterial pressure in sepsis [4]. In addition,
inotropic treatment with the β-1 adrenoceptor agonist
dobutamine has been used to increase cardiac output in
sepsis, although a recent study found dobutamine treat-
ment was associated with increased mortality [5] and* Correspondence: clive.may@florey.edu.au
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only in selected circumstances [4].
Despite the overall beneficial effects of catecholamines
in sepsis, there are indications that a protracted and ex-
cessive increase in sympathetic nerve activity during crit-
ical illness may become maladaptive and exert adverse
effects. For example, an increasing body of evidence sug-
gests that septic myocardial depression and failure can
in part be mediated by excessive and prolonged activa-
tion of the sympathetic nervous system [6,7]. Indeed,
there is evidence in septic shock that inhibiting sympa-
thetic outflow, or blocking the action of catecholamines,
may improve survival. Previous studies in sepsis have
found contrasting effects depending on whether non-
selective or selective β-blockade was used. Non-selective
β-blockade with propranolol, started in the first hour oftral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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induced septic shock [8], and in patients in the late
stages of septic shock propranolol improved blood pres-
sure and urine output [9]. In contrast, in mice with sep-
sis induced by cecal ligation puncture, propranolol
caused clinical deterioration and reduced survival [10].
Selective β1-adrenergic blockade with esmolol has been
tested in patients with septic shock without a major
increase in adverse events [11]. In mice, selective β1-
blockade starting two days before treatment with lipopoly-
saccharide (LPS) or cecal ligation puncture significantly
improved survival, although this effect was substantially
reduced if β-blockers were not given until 6 h after induc-
tion of endotoxemia [12]. In this study, metoprolol
reduced plasma levels of interleukin 6 (IL-6) hepatic
expression of pro-inflammatory cytokines and cardiac ex-
pression of IL-18.
We hypothesised that selective β1-adrenoceptor block-
ade with atenolol would be beneficial in developed
hyperdynamic sepsis in conscious sheep by reducing the
effects of increased cardiac sympathetic activation and
also by decreasing the release of inflammatory cytokines,
which in excess may contribute to multiple organ failure.
We therefore examined the effects of treatment with the
selective β1-adrenoceptor antagonist atenolol on arterial
pressure and pro- and anti-inflammatory plasma cytokine
levels in an ovine model of hyperdynamic, hypotensive
sepsis. Since atenolol may also induce cardiovascular de-
compensation, reduced organ perfusion and organ failure,




Experiments were conducted on nine adult Merino ewes
(35 ± 1 kg), housed in individual metabolic cages, fed
800 g oaten chaff/day with free access to water. The ex-
perimental procedures were approved by the Animal
Ethics Committee of the Howard Florey Institute under
guidelines laid down by the National Health and Medical
Research Council of Australia.
The animals underwent two sterile surgical procedures
under general anaesthesia at intervals of two weeks.
Anaesthesia was induced with intravenous sodium thio-
pentone (10 to 15 mg/kg) for intubation with an endo-
tracheal tube (cuffed size 9) and maintained with oxygen/
air/isoflurane (end tidal isoflurane 1.5 to 2.0%). Fractional
inspired oxygen was altered to maintain SatO2 above 97%,
and ventilation was controlled to maintain end tidal CO2
at approximately 35 mmHg. First, a bilateral carotid arter-
ial loop was created to facilitate arterial cannulation and a
transit-time flow probe (Transonics Systems, Ithaca, NY,
USA) was placed on the pulmonary artery through a left
side 4th intercostal space thoracotomy. During the secondprocedure, a transit-time flow probe was placed on the left
renal artery. The animals were allowed two weeks to re-
cover before the start of experiments. In all operations, an-
imals were treated with intramuscular antibiotics (900 mg,
Ilium Propen; procaine penicillin, Troy Laboratories Ptd
Ltd, Smithfield, NSW, Australia or Mavlab, Slacks Creek,
QLD, Australia) at the start of surgery and then for two
days post-operatively. Post-surgical analgesia was main-
tained with intramuscular injection of flunixin meglumine
(1 mg/kg) (Troy Laboratories or Mavlab) at the start of
surgery, then 8 and 24 hours post-surgery.
The day before the experiment, a Tygon catheter
(Cole-Parmers; Boronia, Australia; ID 1.0 mm, OD 1.5
mm) was inserted 20 cm into the carotid arterial loop to
measure arterial pressure and to obtain blood samples.
Two polythene catheters were inserted into the superior
vena cava via a jugular vein: one for atenolol infusion
(Portex™; Smiths Medical International Ltd., Hythe,
Kent, UK; ID 1.19 mm, OD 1.7 mm) and one for Escher-
ichia coli (E. coli) infusion (Portex™; Smiths Medical
International Ltd.; ID 0.58 mm, OD 0.96 mm). Analog
signals (mean arterial pressure (MAP), heart rate (HR),
cardiac output (CO) and renal blood flow (RBF) were col-
lected on computer using a customized data-acquisition
system (Labview; National Instruments; Austin, TX, USA).
Data were recorded at 100 Hz for 10 seconds every mi-
nute during experiments.
Blood samples from arterial and central lines, and urine
samples, were obtained at the end of 24 hours of baseline,
and then at 8, 10, 12 and 24 hours after induction of sepsis
for measurement of blood gases, blood lactate (ABL
system 625; Radiometer Medical, Copenhagen, Denmark),
plasma creatinine (Cr) and urinary Cr, urea, sodium and
potassium. Urine was collected in 1-hour lots with an au-
tomated urine fraction collector and pooled in 2-hour lots
for measurement of creatinine clearance (CreatCl) and
fractional excretion of sodium (FENa), potassium (FEK)
and urea (FEUN), calculated according to standard formu-
lae: CreatCl = (UCreat x UO)/(PCreat/time(min)) where
UCreat is urine creatinine, PCreat is plasma creatinine
and UO is urine volume over two hours; FENa, FEK and
FEUN = Px/Ux x CrCl x 100 where P is plasma concentra-
tion and U is urine concentration of the substance x (so-
dium, potassium or urea). Oxygen delivery (DO2), oxygen
consumption (VO) and O2 extraction ratio were calcu-
lated as per standard formulae: DO2 = 10 x CO x arterial
O2 concentration, VO2 = 10 x CO x (arterial - venous O2
concentration) and O2 extraction ratio =100 x (arterial -
venous O2 concentration)/(arterial O2 concentration).
Experimental protocol
Following a 24-hour baseline period, sepsis was induced
with an intravenous infusion of live E. coli (2.8 × 109
colony-forming units, CFU) over fifteen minutes at 8
Calzavacca et al. Critical Care 2014, 18:610 Page 3 of 10
http://ccforum.com/content/18/6/610a.m. followed after 3 hours with a continuous infusion of
E. coli (1.26 × 109 CFU/h) for 21 hours. At 8 hours after
the E. coli bolus, when hyperdynamic sepsis had devel-
oped and if heart rate had increased by at least 50%
compared with baseline, the animals randomly received
atenolol (10 mg bolus followed by infusion at 0.125 mg/
kg/h in normal saline at 2 ml/h for 16 h) or no
treatment.
To determine the effectiveness of cardiac β-1 adreno-
ceptor blockade with atenolol, the heart rate responses
to boluses of the selective β1-agonist isoproterenol (30
ng/kg) were determined. Isoproterenol was given the day
before starting the study and at 1, 4, 8 and 16 hours of
atenolol after arterial blood samples were collected. At
the end of the experiment, infusions of E. coli and ateno-
lol were stopped, the animals received intramuscular
gentamicin (150 mg), and all catheters were removed.
Sheep that survived were crossed over the other arm of
the study after at least two weeks.
Cytokine assays
Arterial blood samples were collected into EDTA tubes
on ice at baseline and at 4, 8 and 24 hours of sepsis.
Blood was centrifuged at 3,000 g at 4°C for 10 min and
plasma was aliquoted and frozen at -80°C. Quantification
of interleukin 6 (IL-6) and interleukin 10 (IL-10) levels
were performed using in-house enzyme-linked immuno-
sorbent assays (ELISA), as previously described [13].
Tumour necrosis factor alpha (TNF-α) was measured
using a commercially available ELISA kit (Kingfisher
Biotech Inc., MN, USA). All samples and standards were
assayed in duplicate.
Statistical analysis
Normally distributed data are presented as means ±
standard error of means (SEM) and non-normal data as
geometric mean (95% confidence interval). Statistical
analysis of hemodynamic variables was performed on
baseline values (averages of the 24 hours of baseline),
and two predefined time intervals of interest during
sepsis; the average of the 7th and 8th hour of sepsis
(just before atenolol) and the average of the 23rd and
24th hour (at the end of sepsis). For blood tests, all the
time points were used for statistical comparisons.
Statistical analysis was performed using SAS version
9.2 (SAS Institute Inc., Cary, NC, USA). All variables
were assessed for normality and log-transformed where
appropriate.
Mixed linear modeling was performed with each sheep
treated as a random effect. Main effects were fitted for
time and treatment with an interaction between time
and treatment used to determine if treatments behaved
differently over time. Specific time point comparisons
were performed using post hoc pairwise t tests. To accountfor multiple comparisons, a reduced P value of ≤0.01 was
considered to be statistically significant.Results
Cardiovascular responses
Eight animals per group were studied; one animal in each
group died. In the control group, E. coli induced hyperdy-
namic sepsis as shown by the decrease in MAP over 24
hours with increases in CO and HR and a decrease in
MAP (Figures 1 and 2, Table 1). The hypotension resulted
from peripheral vasodilatation, as shown by the progressive
increase in total peripheral conductance (TPC) (Figure 2).
In the atenolol group, there were comparable changes in
cardiovascular variables to those in the control group at the
time atenolol infusion started.
Treatment of septic sheep with atenolol, caused an im-
mediate decrease in HR from 138 (116,163) beats/min,
which was maintained at this lower level until the end of
the 16-hour infusion (109(92,129) beats/min) (Figure 1,
Table 1). Atenolol also reduced CO within 1 hour and
although HR remained reduced there was a slow in-
crease in CO due to a progressive increase in stroke vol-
ume (SV) during the septic period (Figure 1, Table 1).
Despite the increase in SV in the atenolol group, CO
remained below the level in the control group through-
out the septic period. Although atenolol decreased CO,
the level of MAP during sepsis was similar in the ateno-
lol and control groups (77.2 ± 4.8 vs. 83.2 ± 5.1 mmHg
respectively, P = 0.86) (Figure 2). This was due to the
smaller increase in TPC in the atenolol group, which
although not significant was sufficient to prevent a
greater level of hypotension during atenolol treatment.
Effective β1-adrenergic blockade by atenolol was con-
firmed by demonstrating that the tachycardic response
to a bolus of isoproterenol was blocked. Isoproterenol
(30 ng/kg) given before atenolol increased HR by 43 ±
13 beats/min, while after atenolol there was no signifi-
cant change at any time point (maximum increase 3 ±
1 beats/min).
During the development of sepsis, there were no sig-
nificant changes in partial pressure of oxygen (pO2),
DO2, oxygen volume (VO2) or O2 extraction ratio
(Table 2). By 24 hours of sepsis, DO2 had significantly
increased in the control (P = 0.001) not the atenolol
group (P = 0.016), but there were no differences in DO2
between groups at any time point (see Table 2). Simi-
larly, during sepsis, compared with baseline, VO2 and O2
extraction ratio were not changed, except for O2 extrac-
tion ratio at 24 hours of sepsis that was significantly de-
creased in the control group (P = 0.007). No differences
were observed between groups for VO2 and O2 extrac-
tion ratio. There was a similar threefold increase in ar-
terial lactate in both groups (Table 2).










































































Figure 1 Cardiac effects of atenolol in ovine hyperdynamic
sepsis. Changes in heart rate, cardiac output and stroke volume in
conscious sheep during a 24-hour baseline period and during 24
hours of sepsis induced by intravenous administration of E. coli in a
control group and a group treated with atenolol from 8 to 24 hours
of sepsis. Mean ± SEM, n = 8/group. *P <0.01 for group comparison.

































































Figure 2 In ovine hyperdynamic sepsis atenolol did not cause
further hypotension. Mean arterial pressure and total peripheral
conductance during a 24-hour baseline period and during 24 hours
of sepsis induced by intravenous administration of E. coli in a control
group and a group treated with atenolol from 8 to 24 hours of
sepsis. Mean ± SEM, n = 8/group.
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During sepsis there was a large increase in RBF due to
intense renal vasodilatation as shown by the almost
doubling in renal vascular conductance (RVC) by 24
hours of sepsis (Figure 3). Sepsis caused an initial transient
diuresis followed by oliguria, and the development of acutekidney injury was demonstrated by the increase in plasma
creatinine and decrease in CreatCl (Figure 3, Table 3).
Atenolol had only minor effects on the sepsis-induced
changes in renal hemodynamics and renal function.
Atenolol did not affect RBF or RVC during the inter-
vention period (P = 0.925 and 0.556, respectively). The
initial polyuric response following E. coli was more
pronounced in the control group, but oliguria of a
similar magnitude developed in both groups by the end
of sepsis (Figure 3, Table 3). Plasma creatinine in-
creased more in the atenolol than the control group at
2 and 4 hours after starting atenolol (Table 3, P = 0.003
and <0.001, respectively), and although it tended to be
higher after 16 hours of atenolol, at 24 hours of sepsis,
this difference was not significant (P = 0.072). There
were no significant differences in CreatCl, FENa, FEK
or FEUN between the two groups at any time point
(Table 3).
Table 1 Effect of atenolol on hemodynamic variables in ovine hyperdynamic sepsis
Cardiovascular variables Gp Baseline Sepsis (8 h) Sepsis (24 h)
CO (L/min) A 3.26 (2.80;3.79) 4.01(3.40;4.73)† 4.71 (3.99;5.55)§*
C 3.35 2.88;3.90) 4.13(3.50;4.86)† 5.86 (4.97;6.90)§*
HR (beats/min) A 68 (59;79) 138 (116;163)† 109 (92;129)§*
C 68 (58;78) 133 (113;158)† 152 (128;180)§*
SV (mL/beat) A 49.9 ± 4.3 30.4 ± 4.5† 45.0 ± 4.5§*
C 51.3 ± 4.3 34.2 ± 4.5* 41.3 ± 4.5§*
MAP (mmHg) A 95.4 ± 4.9 96.0 ± 5.1 77.2 ± 4.8§
C 93.7 ± 4.9 95.9 ± 5.1 83.2 ± 5.1§
TPC (L/min/mmHg) A 37.0 ± 4.2 44.2 ± 4.6† 69.2 ± 4.6§
C 38.2 ± 4.4 45.0 ± 4.5† 77.4 ± 4.6)§
RBF (mL/min) A 198 (169;238) 268 (220;325)†* 286 (236;348)§*
C 212 (178;253) 330 (233;400)†* 335 (277;407)§*
RVC (mL/min/mmHg) A 2.11 (1.78;2.50) 2.81(2.31;3.41)† 3.75 (3.09;4.55)§
C 2.32 (1.99;2.75) 3.48(2.88;4.21)† 3.51 (2.93;4.2)§
Measurements were taken during a 24-hour baseline, at 8 hours of sepsis (mean of 7th and 8th hour) and at 24 hours of sepsis (mean of 23rd and 24th hour) in a
control group (C) and a group treated with atenolol from 8 to 24 hours of sepsis (A) (n = 8/group). Values are mean ± SEM for normally distributed or geometric
mean (95% confidence interval) for non-normally distributed variables. †P ≤0.01 for baseline vs. 8 hours of sepsis; §P ≤0.01 for 8 hours of sepsis vs. 24 hours of
sepsis; *P ≤0.01 for Aten vs. Con. CO: cardiac output; HR: heart rate; SV: stroke volume; MAP: mean arterial pressure; TPC: total peripheral conductance; RBF: renal
blood flow; RVC: renal vascular conductance.
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The plasma levels of all cytokines measured were low
during the control period and increased during sepsis
(Figure 4). Plasma TNF-α was significantly increased in
the control group at 8 hours of sepsis (from 0.1 (0.05;
0.18) to 0.41(0.22; 0.74) ng/mL (P <0.01), followed by a
fall towards baseline levels by 24 hours of sepsis, and
there was no significant difference between the control
and atenolol groups over time (Figure 4). Plasma IL-6
was significantly increased in the control group by 8Table 2 Effect of atenolol on oxygen variables in ovine hyper
Biochemical variables Gp Baseline Sepsis (8 h)
pO2 (mmHg) A 90 ± 2 84 ± 2
C 86 ± 3 78 ± 4
SvcO2 (%) A 68.2 ± 2.9 72.3 ± 3.3
C 54.6 ± 4.6 71.2 ± 1.7
DO2 (mL O2/min) A 463 (400;536) 561 (485;650
C 489 (422;566) 590 (502;692
VO2 (mL O2/min) A 167 ± 17 168 ± 17
C 146 ± 17 144 ± 17
O2 E (%) A 31.4 (24.2;40.3) 27.9 (21.2;36
C 33.2 (25.9;42.7) 24.1 (18.7;30
Lactate (mmol/L) A 0.37 (0.24;0.56) 1.20 (0.79;1.8
C 0.39 (0.26;0.59) 1.37 (0.9;2.08
Oxygen variables and arterial lactate during 24 hours of baseline and at 8, 10, 12 an
atenolol from 8 to 24 h of sepsis (n = 8/group). Values are mean ± SEM or geometr
variables, respectively. †P ≤0.01 for time change vs. baseline (within group compari
DO2: O2 delivery; VO2: O2 consumption; O2E: oxygen extraction ratio.hours of sepsis (from 1.04 (0.86; 1.26) to 3.57 (2.96; 4.30)
ng/mL) (P <0.001) and remained elevated at a similar
level until 24 hours of sepsis. The sepsis-induced in-
crease in IL-6 was not changed by treatment with ateno-
lol. Plasma IL-10 also significantly increased by 8 hours
of sepsis from undetectable levels to 5.11 (3.84; 6.82) ng/
mL (P <0.001), but had returned to control levels by 24
hours of sepsis. Treatment with atenolol significantly at-
tenuated the decline in IL-10 compared with control
sheep (P <0.01) (Figure 4).dynamic sepsis
Sepsis (10 h) Sepsis (12 h) Sepsis (24 h)
86 ± 3 86 ± 3 77 ± 2
78 ± 4 79 ± 5 75 ± 6
70.0 ± 2.2 69.4 ± 3.0 72.5 ± 3.9
67.3 ± 6.9 74.8 ± 3.6 72.9 ± 1.2
) 496 (427;577) 513 (441;597) 605 (522;700)
) 597 (508;702) 619 (527;728) 706 (610;818)†
136 ± 17 145 ± 17 142 ± 17
154 ± 19 154 ± 19 143 ± 17
.8) 27.1 (20.7;35.5) 27.3 (20.9; 35.7) 19.3 (15;24.8)
.9) 24.6 (18.4;32.8) 23.8 (17.8;31.8) 22.4 (17.4;28.8)†
3)† 1.61 (1.05;2.49)† 1.57 (1.02;2.41)† 1.31 (0.86;1.99)†
)† 1.54 (1.00;2.37)† 1.55 (1.01;2.39)† 1.34 (0.88;2.04)†
d 24 hours of sepsis in the control group (C) and the group treated with
ic mean (95% confidence interval) for normally and non-normally distributed
son). pO2: partial pressure of oxygen; SvcO2: superior vena cava O2 saturation;












































































Figure 3 Renal effects of atenolol in ovine sepsis. Changes in
renal hemodynamics and urine output in conscious sheep during
a 24-hour baseline period and during 24 hours of sepsis induced
by intravenous administration of E. coli in a control group and a
group treated with atenolol from 8 to 24 hours of sepsis. Mean ±
SEM, n = 8/group.
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The main findings of this study are that in an ovine
model of hyperdynamic sepsis selective β1-adrenoceptor
blockade with atenolol reduced HR and CO, but in-
creased SV. Despite the greater fall in CO during ateno-
lol treatment, the level of hypotension that developed
during sepsis was similar to that in the control group.Atenolol did not alter the sepsis-induced renal vasodilata-
tion and increase in RBF and by the end of the atenolol in-
fusion there was a similar level of acute kidney injury.
Atenolol did not decrease oxygen extraction or increase
arterial lactate levels during sepsis. During sepsis plasma
levels of TNF-α, IL-6 and IL-10 increased; atenolol further
increased the level of the anti-inflammatory cytokine IL-
10, but had no effect on the pro-inflammatory cytokines
TNF-α and IL-6.
There is increasing interest in the effects of sympatho-
lytic drugs in sepsis. Recent human trials have shown
that esmolol treatment in patients with pneumonia and
in septic shock was not associated with major adverse
events despite a reduction in CO and DO2 [11,14]. In
addition, patients on chronic β-blocker therapy admitted
to intensive care with sepsis had reduced mortality
[15]; such findings may promote the more widespread
use of these agents. Similarly, in some experimental
studies, β-blockers improved survival in sepsis [8,12],
but it remains unclear why these drugs, which would
be expected to be detrimental in a hypotensive disease,
had a beneficial action and reduced mortality. It
may depend on the reduction in tachycardia leading
to improved cardiac function [16] or a reduction in
the level of inflammatory cytokines [12,17], since
these molecules can themselves cause organ damage
and even death, independently of the underlying in-
fection [18].
In the present study the dose of atenolol used com-
pletely blocked cardiac β1-adrenoceptors, as judged by
the inhibition of the tachycardic effect of isoproterenol.
Interestingly, this dose of atenolol did not reduce HR to
control levels, indicating that the sepsis-induced tachy-
cardia was not completely dependent on increased car-
diac sympathetic activation. This is in agreement with a
previous study in which we examined the arterial baro-
reflex control of HR in sepsis and concluded that, in
addition to sympathetic activation, a reduction in cardiac
vagal activity and/or a direct effect of cytokines on the
heart accounted for the tachycardia in sepsis [2]. Al-
though atenolol treatment increased SV, this was in-
sufficient to offset the effect of the reduction in HR
and throughout the infusion CO remained lower in
the atenolol group. This reduction in CO did not re-
sult in a greater degree of hypotension during sepsis
because there tended to be less peripheral vasodilata-
tion in the atenolol-treated group. The mechanism for
this is unclear but is most likely to be a peripheral vas-
cular effect because atenolol is hydrophilic and does
not cross the blood-brain barrier. Indeed there is evi-
dence that atenolol causes peripheral vasoconstriction,
which has been proposed to be either by a reflex in-
crease in sympathetic activity or blockade of prejunc-
tional β-adrenoceptors [19].
Table 3 Renal effects of atenolol in ovine sepsis
Renal variables Gp Baseline Sepsis (8 h) Sepsis (10 h) Sepsis (12 h) Sepsis (24 h)
Urine (mL/h) A 24.2 (17.3;33.7) 19.7 (12.2;31.9) 15.8 (9.8;25.6) 10.6 (6.5;17.3) 17.9 (11.0;29.0)
C 22.2 (15.9;31.0) 30.3 (18.5;49.5) 21.2 (13.1;34.4) 14.2 (8.8;23.0) 14.7 (9.1;23.9)
P-creat (μmol/L) A 73 (60;88) 108 (90; 130)† 123 (100;150)† 138 (113;168)† 158 (131;191)†
C 62 (51;75) 84 (70;101) 90 (73;109) 97 (79;118)† 132 (110;160)†
CreatCl (mL/min) A 58.5 ± 7.1 30.9 ± 7.0† 26.5 ± 7.7† 16.4 ± 7.7† 36 ± 7.1
C 66.1 ± 7.1 43.4 ± 7.0† 45.3 ± 7.7 37.5 ± 7.7† 39.7 ± 7.1†
FENa (%) A 0.21 (0.11;0.43) 0.42 (0.21;0.85) 0.32 (0.16;061) 0.51 (0.26;0.98) 0.13 (0.07:0.26)
C 0.18 (0.09;0.39) 0.48 (0.24;0.96) 0.26 (0.14;0.50) 0.20 (0.10;0.38) 0.08 (0.04;0.15)
FEK (%) A 29.7 ± 3.9 25.7 ± 3.9 26.3 ± 4.9 27.9 ± 4.9 27.2 ± 3.9
C 23.7 ± 3.9 25 ± 3.9 20.2 ± 4.9 18.0 ± 4.9 25.9 ± 3.9
FEUN (%) A 48.2 ± 7.6 35.9 ± 7.1 32.3 ± 7.2 31.2 ± 7.2 17.5 ± 7.1†
C 47.9 ± 7.1 42.7 ± 7.1 31.5 ± 7.2 29.4 ± 7.2 22.0 ± 7.1†
Renal function parameters during 24 hours of baseline and at 8, 10, 12 and 24 hours of sepsis in the control group (C) and the group treated with atenolol from 8
to 24 hours of sepsis (n = 8/group).Values are mean ± SEM or geometric mean (95% confidence interval) for normally and not-normally distributed variables,
respectively. †P ≤0.01 for time change vs. baseline (within group comparison). P-creat: plasma creatinine; CreatCl: creatinine clearance; FENa: fractional excretion
of sodium; FEK: fraction excretion of potassium; FEUN: fractional excretion of urea nitrogen. BP values: mean of 24-hour baseline period.
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CO and increase in peripheral resistance, has been re-
ported with propranolol treatment in patients with
hyperdynamic septic shock [9]. The finding that require-
ment for norepinephrine was reduced in patients with
septic shock treated with the β-1 adrenoceptor blocker,
esmolol [20], suggests that treatment with β-blockers
may improve vascular reactivity in sepsis. The present
findings indicate that in sheep with hyperdynamic sepsis
arterial pressure is maintained in the presence of select-
ive cardiac sympathetic denervation, whereas we have
recently shown that selective renal denervation resulted
in a greater degree of hypotension [21].
As we have previously shown, hyperdynamic sepsis
was accompanied by renal vasodilatation, an increase in
RBF and acute kidney failure [22,23]. In septic sheep,
atenolol had minor effects on renal hemodynamics and
renal function despite causing a decrease in CO, prob-
ably because atenolol did not induce a greater degree of
hypotension. Critically, renal function in the atenolol
group, estimated by changes in creatinine clearance,
plasma creatinine, urine output, FENa, FEK and FEUN,
was similar to that in the control group. In addition, in-
dices of tissue perfusion, oxygen consumption and oxy-
gen extraction, were similar in the atenolol and control
groups, as was the increase in blood lactate, indicating
similar levels of disease severity in both groups.
Our findings of simultaneous increases in both pro-
inflammatory and opposing anti-inflammatory cytokines
in this ovine model of sepsis are in accord with findings
in septic patients [24-26]. Although the levels of TNF-α
and IL-10 declined towards normal from 8 to 24 hours of
sepsis, the increase in IL-6 was maintained throughout theseptic period indicating a maintained hyper-inflammatory
phase. Treatment with atenolol did not alter the levels of
TNF-α or IL-6, but increased IL-10, indicating no effect of
β1-adrenoceptor blockade on the pro-inflammatory re-
sponse, but an enhancement of the anti-inflammatory re-
sponse. Currently the mechanism by which atenolol
increased IL-10 in ovine sepsis is unclear since in isolated
macrophages β-agonists stimulate IL-10 release [27,28],
suggesting that in the whole animal other mechanisms
override this effect.
These findings vary from those in murine sepsis where
β1-blockade with metoprolol, started two days before
sepsis, reduced plasma IL-6 and hepatic expression of
key inflammatory genes and reduced mortality, although
if treatment was given 6 hours after endotoxaemia there
was no significant improvement in survival [12]. The β1-
adrenoceptor blocker landiolol reduced both TNF-α and
IL-6 and protected against acute lung injury and cardiac
dysfunction in LPS-treated rats [29]. In rats, following
cecal ligation puncture, esmolol reduced plasma TNF-α,
but not IL-1β, and increased myocardial β1-receptor ex-
pression [16]. These differences from the present study
are probably in part species related considering the
vastly different sensitivity to LPS across species, with
humans and sheep having a 500 to 1,000 times greater
sensitivity than rats and mice [30]. In addition, the dif-
ferent genomic responses to inflammatory stimuli in
mice and humans have also questioned the use of mur-
ine models of sepsis [31].
Our study has both strengths and limitations. The major
strength was that it reproduced severe septic acute kidney
injury in a large conscious mammal and described the
effects of selective β1-adrenoceptor blockade, started at a
Figure 4 Effects of atenolol on plasma cytokine levels in
ovine sepsis. Plasma cytokine levels in conscious sheep during a
24-hour baseline period and during 24 hours of sepsis induced by
intravenous administration of E. coli in a control group and a
group treated with atenolol from 8 to 24 hours of sepsis. Mean ±
SEM, n = 8/group.
Calzavacca et al. Critical Care 2014, 18:610 Page 8 of 10
http://ccforum.com/content/18/6/610clinically relevant time when signs of sepsis were present,
on cardiovascular function, renal function and cytokine
levels. The indirect estimation of glomerular filtration
rate (GFR) using creatinine clearance is of limitedaccuracy, but this method is widely used and clinically
relevant. Furthermore, its changes were concordant
with changes in plasma creatinine. We only investi-
gated the effects of selective β1-adrenocetor blockade
so we are not able to distinguish the extent to which
the findings are due to β1-antagonism or selective
stimulation of β2-adrenoceptors. As in all experimen-
tal animal studies, the relevance of the findings to the
clinical situation is unclear, but as most human sepsis
is hyperdynamic in nature it is likely that this model
has clinical relevance.Conclusions
In experimental hyperdynamic sepsis treatment with
atenolol, started at a clinically relevant time when sep-
sis had developed, did not lead to greater hypotension
even though CO was reduced. Renal function and in-
dices of tissue perfusion were not adversely affected by
atenolol and disease severity appeared similar in the
control and treated groups, indicating the safety of the
treatment. Atenolol did not influence the plasma
levels of the pro-inflammatory cytokines TNF-α and
IL-6 but it induced a greater increase in the anti-
inflammatory cytokine IL-10. These findings indicate
in hyperdynamic sepsis, with a relatively small de-
crease in arterial pressure and a large increase in CO,
that treatment with atenolol had no detrimental
cardiovascular or renal effects and had an anti-
inflammatory effect. Further studies are required to
determine if atenolol is safe in septic shock with circu-
latory failure.Key messages
 In an ovine model of hyperdynamic sepsis atenolol
reduced heart rate and cardiac output
 In sepsis atenolol did not cause a greater degree of
hypotension.
 Atenolol did not reduce renal perfusion or worsen
the development of septic acute renal failure.
 Atenolol did not reduce the sepsis-induced increases
in the inflammatory cytokines TNF-α or IL-6 but
increased the level of the anti-inflammatory
cytokine IL-10.
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